We talk a lot about speed in drug de­vel­op­ment, usu­al­ly in the con­text of the ul­ti­mate goal: get­ting a ther­a­py to pa­tients faster. But there is an­oth­er side to speed that isn’t talked about enough: com­mer­cial val­ue.

A drug may have a 20-year patent term in the U.S., but those 20 years don’t start when the prod­uct launch­es. The patent clock gen­er­al­ly starts run­ning from the ear­li­est ef­fec­tive non­pro­vi­sion­al fil­ing date, po­ten­tial­ly years ear­li­er while the as­set is still mov­ing through non­clin­i­cal de­vel­op­ment, man­u­fac­tur­ing, reg­u­la­to­ry prepa­ra­tion, and clin­i­cal tri­als.

There are im­por­tant nu­ances. Cer­tain patents may qual­i­fy for patent-term ex­ten­sion, and reg­u­la­to­ry ex­clu­siv­i­ties can pro­vide sep­a­rate pro­tec­tions. So, every month saved in de­vel­op­ment does not au­to­mat­i­cal­ly cre­ate an­oth­er month of ex­clu­siv­i­ty.

An im­por­tant ques­tion is: How much pro­tect­ed com­mer­cial life will ac­tu­al­ly be left by the time the prod­uct reach­es the mar­ket?

Ear­ly com­mer­cial years are typ­i­cal­ly spent build­ing aware­ness, se­cur­ing re­im­burse­ment, dri­ving adop­tion, and ex­pand­ing in­to mar­kets and po­ten­tial­ly ad­di­tion­al in­di­ca­tions. Lat­er pro­tect­ed years may there­fore co­in­cide with some of the prod­uct’s strongest com­mer­cial per­for­mance. Then loss of ex­clu­siv­i­ty hap­pens.

Gener­ic or biosim­i­lar com­pe­ti­tion can fun­da­men­tal­ly change the eco­nom­ics of the as­set. Glob­al­Da­ta es­ti­mates that more than $230 bil­lion in U.S. phar­ma­ceu­ti­cal rev­enue could be ex­posed to patent ex­piry be­tween 2025 and 2030. For small mol­e­cules, FDA da­ta show how quick­ly com­pe­ti­tion can af­fect pric­ing: One gener­ic com­peti­tor can be as­so­ci­at­ed with an ap­prox­i­mate­ly 30% price re­duc­tion, while com­pe­ti­tion among five gener­ics is as­so­ci­at­ed with re­duc­tions ap­proach­ing 85%. Bi­o­log­ics fol­low a dif­fer­ent eco­nom­ic pat­tern, but the ex­po­sure is sig­nif­i­cant there too: One analy­sis iden­ti­fied 118 bi­o­log­ics in the U.S. ex­pect­ed to lose patent pro­tec­tion be­tween 2025 and 2034.

Chang­ing how we think about de­vel­op­ment time is nec­es­sary.

If an avoid­able de­lay hap­pens ear­ly in de­vel­op­ment, its im­pact isn’t nec­es­sar­i­ly con­fined to that point on the project plan. The patent ex­piry date doesn’t move be­cause de­vel­op­ment took longer. If that de­lay push­es launch back, you may have trad­ed pro­tect­ed com­mer­cial life at the end.

Il­lus­tra­tive es­ti­mates sug­gest a block­buster gen­er­at­ing $1 bil­lion an­nu­al­ly could have an NPV im­pact of rough­ly $500 mil­lion to $1 bil­lion if launch oc­curred one year ear­li­er. Ac­tu­al val­ue varies by as­set, mar­gins, up­take, re­im­burse­ment, tim­ing, and mod­el­ing as­sump­tions.

De­vel­op­ment ef­fi­cien­cy is more than an op­er­a­tional KPI. It can be a val­ue-cre­ation strat­e­gy.

In­di­vid­ual ac­tiv­i­ties can be ex­e­cut­ed very well while the over­all de­vel­op­ment pro­gram still los­es time. Why? Be­cause the de­lay isn’t nec­es­sar­i­ly in­side the work. It’s be­tween the work.

One or­ga­ni­za­tion con­ducts non­clin­i­cal stud­ies. An­oth­er han­dles bio­analy­sis. An­oth­er man­u­fac­tures clin­i­cal sup­ply. Then there is a clin­i­cal CRO and per­haps an­oth­er provider sup­port­ing reg­u­la­to­ry ac­tiv­i­ties. Every or­ga­ni­za­tion can per­form its piece ex­act­ly as con­tract­ed. But those pieces still need to be con­nect­ed. Con­tracts need to be ne­go­ti­at­ed. Da­ta trans­ferred. Teams on­board­ed. Time­lines rec­on­ciled. Meth­ods de­vel­oped or trans­ferred. And some­times one group waits for an­oth­er to fin­ish some­thing that could have start­ed ear­li­er.

That’s white­space.

White­space doesn’t nec­es­sar­i­ly show up as a fail­ure on any­body’s score­card. No in­di­vid­ual ac­tiv­i­ty may ap­pear de­layed, but the patent clock keeps run­ning, and every avoid­able gap (or white­space) con­sumes time.

In­stead of ask­ing who is do­ing each piece of de­vel­op­ment, what if we start­ed with: Where does this as­set need to get to, what ev­i­dence do we need, and what can we be do­ing now to elim­i­nate the white­space?

If the ob­jec­tive is clin­i­cal proof-of-con­cept, plan­ning can be­gin much ear­li­er. Non­clin­i­cal find­ings can in­form clin­i­cal de­sign, bio­an­a­lyt­i­cal meth­ods can be pre­pared, man­u­fac­tur­ing and clin­i­cal sup­ply aligned, and reg­u­la­to­ry and re­cruit­ment strate­gies ad­vanced along­side the sci­ence.

Not every­thing can, or should, hap­pen in par­al­lel. The op­por­tu­ni­ty is to dis­tin­guish be­tween se­quences that are sci­en­tif­i­cal­ly nec­es­sary and wait­ing that is op­er­a­tional­ly avoid­able.

Reach­ing POC soon­er can mean reach­ing a crit­i­cal val­ue-in­flec­tion point with more patent life re­main­ing, which is im­por­tant both for biotechs seek­ing fund­ing or part­ner­ships and for phar­ma as­sets com­pet­ing for cap­i­tal and pipeline pri­or­i­ty.

Speed isn’t about rush­ing sci­ence. It’s about elim­i­nat­ing the white­space around it. The sci­ence needs time. The white­space be­tween the sci­ence doesn’t.

Rather than treat­ing ser­vices as in­de­pen­dent trans­ac­tions, Al­ta­sciences looks at them as parts of the same de­vel­op­ment con­tin­u­um. Where ap­pro­pri­ate, ac­tiv­i­ties can progress in par­al­lel, with down­stream re­quire­ments an­tic­i­pat­ed ear­li­er, and teams can work from a con­nect­ed pro­gram strat­e­gy.

The Al­ta­sciences Ac­cel­er­a­tion Plat­form can re­duce de­vel­op­ment time­lines by up to 40%, with the po­ten­tial for pro­grams to move from the start of safe­ty as­sess­ment to clin­i­cal POC in as lit­tle as 18 months, com­pared with in­dus­try time­lines of ap­prox­i­mate­ly 27 to 51 months. This means com­pa­nies could gain up to three years of patent life by re­mov­ing white­space. Ac­tu­al time­lines de­pend on the mol­e­cule, in­di­ca­tion, study de­sign, reg­u­la­to­ry re­quire­ments, spon­sor de­ci­sions, and oth­er fac­tors.

Our ob­jec­tive isn’t to make sci­ence hap­pen faster than it should. It’s to re­move time that wasn’t adding val­ue in the first place.

Com­pa­nies can pur­sue many strate­gies as an as­set ap­proach­es loss of ex­clu­siv­i­ty, but they can’t re­cov­er pro­tect­ed com­mer­cial time un­nec­es­sar­i­ly lost dur­ing de­vel­op­ment. Patent-cliff strat­e­gy should start much ear­li­er: by elim­i­nat­ing avoid­able de­lays, un­nec­es­sary hand­offs, and white­space while still giv­ing the sci­ence the time it needs.

Faster de­vel­op­ment doesn’t ex­tend a patent, but it can help pre­serve more of the valu­able com­mer­cial life avail­able once a ther­a­py reach­es the mar­ket.

Ex­plore the Al­ta­sciences Ac­cel­er­a­tion Plat­form, or con­tact our team to dis­cuss your pro­gram.